Influence of heat inactivation of blood samples at 56 ℃ for 30 min on psychiatric drug concentration monitoring

doi:10.3969/j.issn.1673-8640.2022.12.014

Abstract

Abstract:

Objective To investigate the influence of heat inactivation of blood samples at 56 ℃ for 30 min on psychiatric drug concentration monitoring. Methods A total of 60 patients taking olanzapine，quetiapine，risperidone，lithium，valproic acid and clozapine were enrolled. The remaining blood samples were inactivated by heating at 56 ℃ for 30 min and then were determined again. The consistency of the results before and after heat inactivation was analyzed. Result The differences in the results of olanzapine，quetiapine，the sum of risperidone and 9-hydroxyrisperidone，valproic acid，clozapine and N-desmethylclozapine before and after heat inactivation of the samples were not statistically significant（P>0.05），which showed high consistency. The results of blood lithium after heat inactivation were higher than those before heat inactivation（P<0.05），and the consistency was poor before and after heat inactivation. After the calibration by regression equation，the differences between the calibration values and the assay results before heat inactivation were not statistically significant （Z=-0.195，P=0.845），which showed high consistency. Conclusions Heat inactivation at 56 ℃ for 30 min has no effect on the assay results of olanzapine，quetiapine，the sum of risperidone and 9-hydroxyrisperidone，valproic acid，clozapine and N-desmethylclozapine，but it affects the assay results of blood lithium. Blood lithium results still have the reference value after they are corrected by the regression equation.

Key words: Drug concentration monitoring, Heat inactivation, Corona virus disease 2019, Psychotropic drug

CLC Number:

R446.1

SUN Jiaqi, JIN Weifeng, LI Ping, CHEN Shuzi, LIN Ping, LI Dan, CHEN Qing, WANG Mengxia, ZHU Yuxin. Influence of heat inactivation of blood samples at 56 ℃ for 30 min on psychiatric drug concentration monitoring[J]. Laboratory Medicine, 2022, 37(12): 1174-1177.

Figures/Tables 5

References 9

1	国家卫生健康委办公厅. 新型冠状病毒肺炎诊疗方案(第八版)[EB/OL]. (2021-05-11)[2022-01-03]. http://www.gov.cn/xinwen/2021-05/14/content_5606469.htm1.
2	上海市医疗机构临床实验室质量管理规范[S]. 上海: 上海市临床检验中心, 2018.
3	WANG R, ZHANG Q, GE J, et al. Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and the ability to use ACE2 receptors from additional species[J]. Immunity, 2021, 54(7):1611-1621.e5. DOI PMID
4	VARATHARAJ A, THOMAS N, ELLUL M A, et al. Neurological and neuropsychiatric complications of COVID-19 in 153 patients:a UK-wide surveillance study[J]. Lancet Psychiatry, 2020, 7(10):875-882. DOI URL
5	TAQUET M, GEDDES J R, HUSAIN M, et al. 6-Month neurological and psychiatric outcomes in 236 379 survivors of COVID-19:a retrospective cohort study using electronic health records[J]. Lancet Psychiatry, 2021, 8(5):416-427. DOI URL
6	HIEMKE C, BERGEMANN N, CLEMENT H W, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology:update 2017[J]. Pharmacopsychiatry, 2018, 51(1-2):9-62. DOI URL
7	OELLERICH M, KANZOW P, WALSON P D. Therapeutic drug monitoring-key to personalized pharmacotherapy[J]. Clin Biochem, 2017, 50(7-8):375-379. DOI URL
8	熊歆, 张现化, 李晓娜, 等. 新型冠状病毒肺炎疫情下治疗药物监测实验室气溶胶产生风险及应对[J]. 中国药业, 2020, 29(7):45-49.
9	颜世铭. 微量元素导论[M]. 上海: 同济大学出版社,1992.

项目	奥氮平/（ng/mL）	利培酮与9-羟利培酮之和/（ng/mL）	血锂/（nmol/L）	丙戊酸/（μg/mL）
加热灭活前	53.56（17.42~88.21）	30.10（15.27~62.26）	0.67（0.44~0.89）	63.95（42.78~105.48）
加热灭活后	55.72（18.14~93.47）	31.20（15.56~61.95）	0.70（0.46~0.91）	63.80（42.72~104.10）
Z值	-1.320	-1.280	-2.920	-1.950
P值	0.186	0.202	0.003	0.051
项目	喹硫平/（ng/mL）	氯氮平/（ng/mL）	N-去甲氯氮平/（ng/mL）
加热灭活前	234.17（56.35~539.12）	454.95（272.27~663.28）	176.51（115.76~229.81）
加热灭活后	227.04（55.78~515.64）	457.21（271.81~639.26）	173.27（114.89~236.26）
Z值	-1.870	-1.855	-0.732
P值	0.062	0.064	0.464

项目	奥氮平/（ng/mL）	利培酮与9-羟利培酮之和/（ng/mL）	血锂/（nmol/L）	丙戊酸/（μg/mL）
加热灭活前	53.56（17.42~88.21）	30.10（15.27~62.26）	0.67（0.44~0.89）	63.95（42.78~105.48）
加热灭活后	55.72（18.14~93.47）	31.20（15.56~61.95）	0.70（0.46~0.91）	63.80（42.72~104.10）
Z值	-1.320	-1.280	-2.920	-1.950
P值	0.186	0.202	0.003	0.051
项目	喹硫平/（ng/mL）	氯氮平/（ng/mL）	N-去甲氯氮平/（ng/mL）
加热灭活前	234.17（56.35~539.12）	454.95（272.27~663.28）	176.51（115.76~229.81）
加热灭活后	227.04（55.78~515.64）	457.21（271.81~639.26）	173.27（114.89~236.26）
Z值	-1.870	-1.855	-0.732
P值	0.062	0.064	0.464

项目	例数	加热灭活前/ （ng/mL）	校准值/ （ng/mL）
低值	10	0.47（0.455~0.485）	0.46（0.430~0.505）
中值	10	0.65（0. 565~0.695）	0.64（0.550~0.690）
高值	10	0.93（0.885~1.145）	0.94（0.900~1.120）

项目	例数	加热灭活前/ （ng/mL）	校准值/ （ng/mL）
低值	10	0.47（0.455~0.485）	0.46（0.430~0.505）
中值	10	0.65（0. 565~0.695）	0.64（0.550~0.690）
高值	10	0.93（0.885~1.145）	0.94（0.900~1.120）

[1]	XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146.
[2]	YUE Caidie, LI Junyan, DING Aijun, XIE Li, ZENG Weikun. Research progress of rapid determination methods for SARS-CoV-2 antigen [J]. Laboratory Medicine, 2023, 38(1): 87-93.
[3]	HUANG Fei, ZHANG Chunyan, GUO Wei, PAN Baishen, WANG Beili. Status and problems of SARS-CoV-2 nucleic acid detection [J]. Laboratory Medicine, 2021, 36(5): 554-559.
[4]	HU Senan, TAN Junfeng, PENG Chang, AI Honghong, LI Dan. Role of blood glucose variability in the prognosis of severe corona virus disease 2019 patients [J]. Laboratory Medicine, 2021, 36(4): 400-403.
[5]	WANG Bin. Correlation between neutrophil-to-lymphocyte ratio and short-term poor prognosis in patients with corona virus disease 2019 [J]. Laboratory Medicine, 2021, 36(3): 275-280.
[6]	ZHU Chuanxin, ZHOU Yuping, HE Yan, ZHOU Qin. Diagnostic role of NLR,CRP,PCT,DD and NT-proBNP in severe corona virus disease 2019 [J]. Laboratory Medicine, 2021, 36(2): 190-193.
[7]	LI Shichao, SHEN Liang, WANG Chunhua, TONG Yanfei, ZHANG Ji. Diagnostic value of SARS-CoV-2 antibody to COVID-19：a meta-analysis [J]. Laboratory Medicine, 2021, 36(1): 39-43.
[8]	FAN Jian, GUO Ying, QI Weiqiang, HAO Menglu, ZHANG Tengfei, ZHU Zhaoqin. Analysis on the absolute value of lymphocyte in COVID-19 patients before and after recovery in Shanghai [J]. Laboratory Medicine, 2021, 36(1): 44-47.
[9]	LIAO Shengjun, XU Xianqun, ZHAO Jin, LI Siwei, QIU Xueping, CHEN Liangjun, LI Yirong. Correlation between some laboratory indexes and severity of COVID-19 in 144 patients [J]. Laboratory Medicine, 2021, 36(1): 48-52.
[10]	ZHU Chuanxin, ZHOU Yuping, ZHOU Qin, ZHOU Guifeng. Early diagnosis value of NLR,PCT and CRP combined determination for COVID-19 [J]. Laboratory Medicine, 2021, 36(1): 53-56.
[11]	WANG Xiaowu, GAO Yong, WU Dong. Prediction of severe corona virus disease 2019 by coagulation indicators [J]. Laboratory Medicine, 2021, 36(1): 57-59.
[12]	ZHANG Tengfei, QI Weiqiang, LING Yun, ZAI Shubei, WANG Yan, FAN Jian, ZHANG Bei, ZHU Zhaoqin. Correlation between urinary protein and disease progression in COVID-19 patients [J]. Laboratory Medicine, 2020, 35(9): 872-874.
[13]	HUANG Shaokun, ZHONG Qingyang, ZHU Haipeng, LUO Rundi, ZHANG Jianming. Roles of dynamic monitoring of SARS-CoV-2 antibodies in the diagnosis of COVID-19 [J]. Laboratory Medicine, 2020, 35(9): 895-899.
[14]	ZHAO Minghai, LI Xin, WEI Dong, LUO Min, ZHANG Yajie, YANG Yiqi, ZHENG Lei. Influence of dry heat inactive treatment for the determination of inflammatory indicators related with corona virus disease 2019 [J]. Laboratory Medicine, 2020, 35(9): 924-927.
[15]	CHANG Zhongyong, LIAO Guolin, WANG Qiang, YANG Weibin. Analysis of mixed infection with common respiratory tract pathogens in patients with corona virus disease 2019 [J]. Laboratory Medicine, 2020, 35(8): 775-777.